These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 18207285)
1. A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors. Lu IL; Tsai KC; Chiang YK; Jiaang WT; Wu SH; Mahindroo N; Chien CH; Lee SJ; Chen X; Chao YS; Wu SY Eur J Med Chem; 2008 Aug; 43(8):1603-11. PubMed ID: 18207285 [TBL] [Abstract][Full Text] [Related]
2. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening. Al-Masri IM; Mohammad MK; Taha MO ChemMedChem; 2008 Nov; 3(11):1763-79. PubMed ID: 18989859 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. Al-masri IM; Mohammad MK; Tahaa MO J Enzyme Inhib Med Chem; 2009 Oct; 24(5):1061-6. PubMed ID: 19640223 [TBL] [Abstract][Full Text] [Related]
4. Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors. Longenecker KL; Stewart KD; Madar DJ; Jakob CG; Fry EH; Wilk S; Lin CW; Ballaron SJ; Stashko MA; Lubben TH; Yong H; Pireh D; Pei Z; Basha F; Wiedeman PE; von Geldern TW; Trevillyan JM; Stoll VS Biochemistry; 2006 Jun; 45(24):7474-82. PubMed ID: 16768443 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors. Wang L; Zhang B; Ji J; Li B; Yan J; Zhang W; Wu Y; Wang X Eur J Med Chem; 2009 Aug; 44(8):3318-22. PubMed ID: 19375196 [TBL] [Abstract][Full Text] [Related]
6. Structure-based virtual screening for low molecular weight chemical starting points for dipeptidyl peptidase IV inhibitors. Ward RA; Perkins TD; Stafford J J Med Chem; 2005 Nov; 48(22):6991-6. PubMed ID: 16250657 [TBL] [Abstract][Full Text] [Related]
7. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Pei Z Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568 [TBL] [Abstract][Full Text] [Related]
9. (3R)-3-amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Nitta A; Fujii H; Sakami S; Nishimura Y; Ohyama T; Satoh M; Nakaki J; Satoh S; Inada C; Kozono H; Kumagai H; Shimamura M; Fukazawa T; Kawai H Bioorg Med Chem Lett; 2008 Oct; 18(20):5435-8. PubMed ID: 18819797 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Kim SJ; Nian C; Doudet DJ; McIntosh CH Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors. Wu D; Jin F; Lu W; Zhu J; Li C; Wang W; Tang Y; Jiang H; Huang J; Liu G; Li J Chem Biol Drug Des; 2012 Jun; 79(6):897-906. PubMed ID: 22381062 [TBL] [Abstract][Full Text] [Related]
12. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor. Gupta RC; Chhipa L; Mandhare AB; Zambad SP; Chauthaiwale V; Nadkarni SS; Dutt C Bioorg Med Chem Lett; 2009 Sep; 19(17):5021-5. PubMed ID: 19643608 [TBL] [Abstract][Full Text] [Related]
13. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 Musoev A; Numonov S; You Z; Gao H Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858 [TBL] [Abstract][Full Text] [Related]
14. Selectivity among dipeptidyl peptidases of the S9b family. Bjelke JR; Kanstrup AB; Rasmussen HB Cell Mol Biol (Noisy-le-grand); 2006 Dec; 52(4):3-7. PubMed ID: 17543192 [TBL] [Abstract][Full Text] [Related]
15. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Kirby M; Yu DM; O'Connor S; Gorrell MD Clin Sci (Lond); 2009 Sep; 118(1):31-41. PubMed ID: 19780719 [TBL] [Abstract][Full Text] [Related]
16. New leads for DPP IV inhibition: structure-based pharmacophore mapping and virtual screening study. Almasri IM; Taha MO; Mohammad MK Arch Pharm Res; 2013 Nov; 36(11):1326-37. PubMed ID: 23918649 [TBL] [Abstract][Full Text] [Related]
17. Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors. Park WS; Kang SK; Jun MA; Shin MS; Kim KY; Rhee SD; Bae MA; Kim MS; Kim KR; Kang NS; Yoo SE; Lee JO; Song DH; Silinski P; Schneider SE; Ahn JH; Kim SS Bioorg Med Chem Lett; 2011 Mar; 21(5):1366-70. PubMed ID: 21306895 [TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors. Zhu Y; Xia S; Zhu M; Yi W; Cheng J; Song G; Li Z; Lu P Eur J Med Chem; 2010 Nov; 45(11):4953-62. PubMed ID: 20800322 [TBL] [Abstract][Full Text] [Related]
19. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Deacon CF Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107 [TBL] [Abstract][Full Text] [Related]
20. Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors. Qiao L; Baumann CA; Crysler CS; Ninan NS; Abad MC; Spurlino JC; Desjarlais RL; Kervinen J; Neeper MP; Bayoumy SS; Williams R; Deckman IC; Dasgupta M; Reed RL; Huebert ND; Tomczuk BE; Moriarty KJ Bioorg Med Chem Lett; 2006 Jan; 16(1):123-8. PubMed ID: 16236500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]